The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

A clinical trial using engineered immune cells to hunt cancer cells has reported impressive results for solid tumours, a type ...

In recent years, the therapeutic landscape for hematological malignancies has undergone a profound transformation, driven by the development and regulatory ...

Age-associated nicotinamide adenine dinucleotide decline drives CAR-T cell failure. Chimeric antigen receptor (CAR) T cell therapy is one of the most promising cancer treatments.

This study, published in Cell, demonstrates that engineering T-cells to express both a Chimeric Antigen Receptor (CAR) and a T-cell Receptor (TCR) can improve their ability to distinguish between ...

CAR T cell immunotherapy, which uses a patient's own modified immune cells to find and destroy cancer cells, can produce ...

Gut bacteria produce metabolites that influence drug metabolism and affect immune cell function, potentially enhancing or ...

A new study published in Nature Cancer has found that aging significantly affects the efficacy of CAR-T cell therapy — a ...

An international clinical trial shows an innovative CAR-T cell immunotherapy is promising against aggressive T cell cancers and has manageable side effects.